Multivariable analysis of DNMT3A as a prognostic marker for OS and RFS
| . | OS . | RFS . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| DNMT3A | 1.82 (1.2-2.7) | .003 | 2.20 (1.4-3.3) | < .001 |
| FLT3ITD | 1.67 (1.2-2.3) | .002 | 1.40 (0.9-2.0) | .060 |
| NPM1mut | 0.44 (0.2-0.6) | < .001 | 0.40 (0.2-0.6) | < .001 |
| CEBPADM | 0.34 (0.1-0.7) | .005 | 0.40 (0.2-0.8) | .017 |
| NRASmut | 0.78 (0.4-1.3) | .341 | 0.70 (0.3-1.3) | .310 |
| IDH1mut | 0.76 (0.4-1.3) | .330 | 0.87 (0.5-1.5) | .630 |
| IDH2mut | 0.69 (0.4-1.1) | .170 | 0.70 (0.4-1.2) | .220 |
| EVI1 | 1.43 (0.8-2.3) | .145 | 1.59 (0.8-2.8) | .120 |
| WT1mut | 1.23 (0.7-2.1) | .430 | 1.40 (0.8-2.6) | .180 |
| cKitmut | 0.54 (0.2-1.3) | .190 | 1.22 (0.5-2.8) | .630 |
| Cytogenetic risk group* | 1.77 (0.9-3.2) | .050 | 2.70 (1.3-5.4) | .003 |
| Age | 1.01 (0.9-1.0) | .125 | 1.001 (0.9-1.0) | .970 |
| WBC count | 1.002 (1.001-1.003) | .002 | 1.001 (0.9-1.0) | .140 |
| . | OS . | RFS . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| DNMT3A | 1.82 (1.2-2.7) | .003 | 2.20 (1.4-3.3) | < .001 |
| FLT3ITD | 1.67 (1.2-2.3) | .002 | 1.40 (0.9-2.0) | .060 |
| NPM1mut | 0.44 (0.2-0.6) | < .001 | 0.40 (0.2-0.6) | < .001 |
| CEBPADM | 0.34 (0.1-0.7) | .005 | 0.40 (0.2-0.8) | .017 |
| NRASmut | 0.78 (0.4-1.3) | .341 | 0.70 (0.3-1.3) | .310 |
| IDH1mut | 0.76 (0.4-1.3) | .330 | 0.87 (0.5-1.5) | .630 |
| IDH2mut | 0.69 (0.4-1.1) | .170 | 0.70 (0.4-1.2) | .220 |
| EVI1 | 1.43 (0.8-2.3) | .145 | 1.59 (0.8-2.8) | .120 |
| WT1mut | 1.23 (0.7-2.1) | .430 | 1.40 (0.8-2.6) | .180 |
| cKitmut | 0.54 (0.2-1.3) | .190 | 1.22 (0.5-2.8) | .630 |
| Cytogenetic risk group* | 1.77 (0.9-3.2) | .050 | 2.70 (1.3-5.4) | .003 |
| Age | 1.01 (0.9-1.0) | .125 | 1.001 (0.9-1.0) | .970 |
| WBC count | 1.002 (1.001-1.003) | .002 | 1.001 (0.9-1.0) | .140 |
Survival analysis was performed on young patients with newly diagnosed young AML (< 60 years) from which APL cases were excluded (n = 415). Age and WBC count were analyzed as continuous variables in the multivariate analysis.
OS indicates overall survival; RFS, relapse-free survival; HR, hazard ratio; CI, confidence interval; and WBC, white blood cell.
Cytogenetic risk group favorable includes t(8;21), inv(16), or t(16;16); adverse, inv(3)/t(3;3), t(6;9), 11q23 abnormalities other than t(9;11), del5, del5(q), del7, del7(q), t(9;22), or monosomal karyotypes (MK); and intermediate, the remaining AML cases.